Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

CRANBURY, NJ, USA I March 31, 2025 I Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss experienced minimal lean muscle mass loss as they lost weight across six months of treatment.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established atherosclerotic disease, CKD, or both.

Two undergraduate medicine students at University of Galway have led a major study examining how cardioprotective ...

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

The Company reported positive topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP ...

Specifically, 46 patients were assigned to the MC4R plus GLP-1/GIP co-administration group ... and gastrointestinal side effects." While GLP-1 receptor agonists are widely used to treat obesity ...

The data also showed that low dose MC4R agonist bremelanotide stopped the rapid weight regain seen after ending GLP-1/GIP tirzepatide treatment." Topline data results from the study were highly ...